NASDAQ:KALV

Kalvista Pharmaceuticals Stock Forecast

etoro logo Buy KALV
*Your capital is at risk
$27.00
+0 (+0%)
At Close: Jul 31, 2026
Add KALV to Watchlist?
Some Reasons Why To Add KALV:
  • +104.4% price growth over the last year
  • High gross margin of 92.0%
  • Lower volatility than the market (beta -0.29)

KALV Performance

FAQ

What is the symbol for KalVista Pharmaceuticals Inc Stock and on which exchange is it traded?
The symbol for KalVista Pharmaceuticals Inc is KALV and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell KalVista Pharmaceuticals Inc Stock?
KalVista Pharmaceuticals Inc holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy KalVista Pharmaceuticals Inc Stock?
KalVista Pharmaceuticals Inc Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy KalVista Pharmaceuticals Inc Stock.

What's the current price of KalVista Pharmaceuticals Inc Stock?
As of the end of day on the Jul 31, 2026, the price of an KalVista Pharmaceuticals Inc (KALV) share was $27.00.

What is the 52-week high and low for KalVista Pharmaceuticals Inc Stock?
The 52-week high for KalVista Pharmaceuticals Inc Stock is $27.00 and the 52-week low is $10.41.

What is the market capitalization of KalVista Pharmaceuticals Inc Stock?
As of the Jul 31, 2026, the market capitalization of KalVista Pharmaceuticals Inc is 1.438B.

When is the next earnings date for KalVista Pharmaceuticals Inc?
The upcoming earnings date for KalVista Pharmaceuticals Inc is Aug 13, 2026.
Click to get the best stock tips daily for free!
ABOUT KALVISTA PHARMACEUTICALS INC
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed ...
GOLDEN STAR
Ticker Change Signal Date
FOX
$50.81
2.22% Jul 27
UNFI
$49.05
3.63% Jul 27
BIIB
$202.19
0.376% Jul 24
TSCO
$30.32
1.48% Jul 23
S
SW
$43.71
5.17% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE